RESUMEN
AIMS: To determine if diabetic lipaemia is caused by loss of function mutations in the lipoprotein lipase gene, LPL. METHODS: We conducted a case-control study over 2 years in two tertiary care hospitals in South Australia. Six patients with a history of diabetic lipaemia and 12 control subjects, with previous diabetic ketoacidosis and peak triglyceride concentrations < 2.4 mmol/l were included. Participants were well at the time of study investigations. RESULTS: Only one patient with lipaemia had a loss of function mutation in LPL and no functional mutations in APOC2 or GPIHBP1 were identified. The mean lipoprotein lipase concentration was lower in patients with diabetic lipaemia than in control subjects (306 vs. 484 µg/l, P = 0.04). The mean fasting C-peptide concentration was higher in patients with diabetic lipaemia than in control subjects (771 vs. 50 pmol/l; P = 0.001). CONCLUSIONS: Lipoprotein lipase deficiency in patients with a history of diabetic lipaemia was predominantly quantitative, rather than secondary to mutations in LPL, APOC2 or GPIHBP1. The majority of patients with severe hypertriglyceridaemia in diabetic ketoacidosis may have ketosis-prone Type 2, rather than Type 1, diabetes.
Asunto(s)
Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Hiperlipidemias/genética , Lipoproteína Lipasa/genética , Adulto , Anciano , Apolipoproteína C-II/genética , Estudios de Casos y Controles , HDL-Colesterol/metabolismo , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 2/complicaciones , Cetoacidosis Diabética/metabolismo , Femenino , Genotipo , Humanos , Hiperlipidemias/etiología , Hiperlipidemias/metabolismo , Hipertrigliceridemia/etiología , Hipertrigliceridemia/genética , Hipertrigliceridemia/metabolismo , Lipoproteína Lipasa/metabolismo , Masculino , Persona de Mediana Edad , Mutación , Receptores de Lipoproteína/genética , Estudios Retrospectivos , Adulto JovenRESUMEN
Product information is often at odds with current evidence and guidelines and inconsistent between products and within classes. There is no single 'owner' responsible for up-to-date medicines product information. Outdated product information increases the risk of inappropriate prescribing.
Asunto(s)
Etiquetado de Medicamentos/normas , Medicamentos Genéricos/efectos adversos , Medicamentos Genéricos/normas , Errores de Medicación/prevención & control , Etiquetado de Medicamentos/métodos , Etiquetado de Medicamentos/tendencias , Humanos , Errores de Medicación/tendenciasRESUMEN
BACKGROUND: The thiopurines azathioprine and 6-mercaptopurine are recommended for maintenance of remission in inflammatory bowel disease (IBD). Measurement of concentrations of the metabolites 6-thioguanine nucleotide and 6-methylmercaptopurine helps delineate interindividual variation in metabolism that may underlie variability in efficacy and toxicity. AIMS: We aimed to perform a retrospective observational study to determine the utility of thiopurine metabolite testing following its introduction into South Australia. METHODS: All patients having thiopurine metabolite tests done at Flinders Medical Centre between November 2008 and January 2010 were identified. Case notes of patients with testing done in the context of treatment for IBD were interrogated to determine the reason for testing, clinical context and outcome. RESULTS: One hundred and fifty-one patients were identified with thiopurine metabolite testing for IBD with 157 testing episodes. Eighty (51.0%) had testing done for flare or inefficacy, 18 (11.5%) for adverse effects, 5 (3.2%) for a combination of inefficacy and adverse effects, and 54 (34.4%) for routine or other reasons. Testing was followed by improved outcomes of increased efficacy, reduced toxicity or change to alternative therapy in 55.0% of the inefficacy/flare group, 27.8% of the suspected adverse reaction group, 60.0% of the combination group, and 13.0% of the routine/other group. Allopurinol was used as cotherapy in 16 patients and led to marked improvements in metabolite concentrations. CONCLUSIONS: Thiopurine metabolite testing has quickly become established in South Australia. When used for inefficacy or adverse effects, it often leads to improved outcomes. Prospective studies are needed to determine whether routine testing to guide dosing is of benefit.
Asunto(s)
Nucleótidos de Guanina/metabolismo , Enfermedades Inflamatorias del Intestino/metabolismo , Enfermedades Inflamatorias del Intestino/terapia , Mercaptopurina/análogos & derivados , Tionucleótidos/metabolismo , Adulto , Biomarcadores/metabolismo , Manejo de la Enfermedad , Femenino , Humanos , Enfermedades Inflamatorias del Intestino/diagnóstico , Masculino , Mercaptopurina/metabolismo , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
BACKGROUND: There is limited consensus regarding optimal glucocorticoid administration for pituitary surgery to prevent a potential adrenal crisis. AIM: To assess the investigation and management of the hypothalamic-pituitary-adrenal (HPA) axis in patients undergoing trans-sphenoidal hypophysectomy in Australasia. METHODS: A questionnaire was sent to one endocrinologist at each of 18 centres performing pituitary surgery in Australasia. Using hypothetical case vignettes, respondents were asked to describe their investigation and management of the HPA axis for a patient with a: non-functioning macroadenoma and intact HPA axis, non-functioning macroadenoma and HPA deficiency and growth hormone secreting microadenoma undergoing trans-sphenoidal hypophysectomy. RESULTS: Responses were received from all 18 centres. Seventeen centres assess the HPA axis preoperatively by measuring early morning cortisol or a short synacthen test. Preoperative evaluation of the HPA status influenced glucocorticoid prescription by 10 centres, including 2/18 who would not prescribe perioperative glucocorticoids for a patient with a macroadenoma and an intact HPA axis. Tumour size influenced glucocorticoid prescribing patterns at 7/18 centres who prescribe a lower dose or no glucocorticoids for a patient with a microadenoma. Choice of investigations for definitive postoperative assessment of the HPA axis varied with eight centres requesting an insulin tolerance test, four centres a 250 µg short synacthen test and six centres requesting other tests. CONCLUSIONS: There is wide variability in the investigation and management of perioperative glucocorticoid requirements for patients undergoing pituitary surgery in Australasia. This may reflect limited evidence to define optimal management and that further well-designed studies are needed.
Asunto(s)
Adenoma/sangre , Sistema Hipotálamo-Hipofisario/metabolismo , Atención Perioperativa/métodos , Neoplasias Hipofisarias/sangre , Neoplasias Hipofisarias/terapia , Sistema Hipófiso-Suprarrenal/metabolismo , Adenoma/epidemiología , Adenoma/terapia , Australasia/epidemiología , Recolección de Datos , Manejo de la Enfermedad , Glucocorticoides/uso terapéutico , Humanos , Hidrocortisona/sangre , Neoplasias Hipofisarias/epidemiologíaAsunto(s)
Desamino Arginina Vasopresina/efectos adversos , Hiponatremia/inducido químicamente , Complicaciones Posoperatorias/inducido químicamente , Convulsiones/etiología , Enfermedades de von Willebrand/tratamiento farmacológico , Anciano , Desamino Arginina Vasopresina/administración & dosificación , Desamino Arginina Vasopresina/uso terapéutico , Diuresis , Relación Dosis-Respuesta a Droga , Ingestión de Líquidos , Procedimientos Quirúrgicos Electivos , Femenino , Personal de Salud/educación , Humanos , Hiperparatiroidismo Primario/complicaciones , Hiperparatiroidismo Primario/cirugía , Hiponatremia/complicaciones , Hiponatremia/prevención & control , Paratiroidectomía , Complicaciones Posoperatorias/prevención & controlRESUMEN
BACKGROUND: A higher anticholinergic risk score (ARS) is associated with an increased risk of anticholinergic adverse effects in elderly patients. It is unknown whether factors other than the use of anticholinergic drugs determine the ARS. METHODS: A comprehensive medical record review was conducted in 155 consecutive hospitalised patients (median age 79.0 years, interquartile range 66.0-86.0). Information was collected on: demographics; clinical characteristics (including medications and their doses); history of anticholinergic-induced adverse effects; and biochemical markers of hepatic and renal function (serum albumin concentrations and estimated glomerular filtration rate, eGFR). The ARS was calculated for each patient using a standard scoring approach and Poisson regression was used for identifying variables associated with the ARS. RESULTS: Patients with an ARS >or= 3 had a lower eGFR (p = 0.012) and were receiving more non-anticholinergic drugs (p < 0.001) than patients with an ARS < 3. In addition to being prescribed more anticholinergic drugs, patients with ARS >or= 3 were prescribed high doses of these drugs more often than patients with ARS < 3 (41.3% vs. 26.9%, p = 0.034). A higher number of non-anticholinergic drugs (p < 0.001), a lower serum albumin concentration (p = 0.014), and a lower eGFR (p = 0.012) were independently associated with a higher ARS. CONCLUSIONS: Polypharmacy, hypoalbuminaemia and low eGFR are independently associated with the ARS. Patients with a higher ARS are also prescribed higher doses of anticholinergic medications than those with lower ARS.
Asunto(s)
Lesión Renal Aguda/inducido químicamente , Antagonistas Colinérgicos/efectos adversos , Hipoalbuminemia/inducido químicamente , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Análisis de Regresión , Medición de RiesgoAsunto(s)
Creatinina/metabolismo , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Nefropatías Diabéticas/metabolismo , Inhibidores de la Dipeptidil-Peptidasa IV/farmacocinética , Fallo Renal Crónico/metabolismo , Purinas/farmacocinética , Quinazolinas/farmacocinética , Femenino , Humanos , MasculinoAsunto(s)
Monitoreo de Drogas/métodos , Monitoreo de Drogas/normas , Monitoreo de Drogas/tendencias , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Atención al Paciente/métodos , Atención al Paciente/normas , Atención al Paciente/tendencias , Preparaciones Farmacéuticas/administración & dosificaciónRESUMEN
OBJECTIVE: To assess the risk of important cardiac events while waiting for coronary artery bypass surgery (CABG) in relation to the New Zealand priority scoring system; to compare clinical characteristics of patients referred for CABG in New Zealand with those in Ontario, Canada; and to compare the New Zealand priority scoring system for CABG with the previously validated Ontario urgency score. DESIGN: Analysis of outcomes in a consecutive case series of patients referred for CABG. SETTING: University hospital. PATIENTS: All 324 patients from Christchurch Hospital wait listed for isolated CABG between 1 January 1994 and 31 December 1995. MAIN OUTCOME MEASURES: Death, myocardial infarction, and unstable angina while waiting for CABG; waiting time to surgery. RESULTS: Clinical characteristics at referral were very similar, but median waiting time was longer in New Zealand than in a large Canadian case series (212 days v 17 days). While waiting for elective CABG, 44% (114/257) of New Zealand patients had cardiac events: death 4% (13/257), non-fatal myocardial infarction 6% (16/257), readmission with unstable angina 34% (87/257). Priority scores did not predict cardiac events while waiting for CABG. Indeed, death or non-fatal myocardial infarction occurred in 4% (3/76) and 8% (6/76), respectively, of those with priority scores < 35. These people are no longer eligible for publicly funded surgery in New Zealand. CONCLUSIONS: Very long waiting times for CABG are associated with frequent cardiac events, at considerable cost to both patients and health care providers. Priority scores may facilitate comparison between countries but such scores did not predict clinical events while waiting.
Asunto(s)
Puente de Arteria Coronaria , Enfermedad Coronaria/fisiopatología , Selección de Paciente , Anciano , Canadá/epidemiología , Enfermedad Coronaria/mortalidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nueva Zelanda/epidemiología , Recurrencia , Estudios Retrospectivos , Medición de Riesgo , Listas de EsperaRESUMEN
Sex hormone-binding globulin (SHBG) and corticosteroid-binding globulin (CBG) circulate in plasma and bind their cognate ligands with high affinity, offering a steroid delivery system to target tissues by a variety of mechanisms. Analysis of these steroid-binding proteins is gaining importance in the clinical setting, although more information is warranted on their diurnal and biological variation. This study shows that plasma SHBG (in normal subjects) exhibits little diurnal or biological variation over the 30 day period studied, in contrast to CBG, where plasma levels peak in the early afternoon. This leads to attenuation of the diurnal free cortisol level rhythm compared to total cortisol. We also show that plasma CBG is significantly lower in male subjects with the metabolic syndrome compared to age-matched lean counterparts, and may therefore act as a surrogate marker of insulin resistance. The consequence of lower levels of CBG in these obese male subjects is reflected by higher levels of circulating free cortisol, potentially offering a more favourable environment for adipogenesis.